NCT03050190Terminated
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The study will evaluate safety and efficacy of a 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
- Status (registry)
- Terminated
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 8 Feb 2017
- Start date
- 1 May 2025
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- NCT number
- NCT03050190
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- accompanied with other active diseases, the treatment is difficult to correct.
- bacteria, fungus, or virus infection, unable to control.
- people living with HIV.
- active HBV and HCV infection.
Other
- of pregnancy and nursing mothers.
- before entering the test of the use of glucocorticoid systemic treatment within a week.
- confirmed before used CAR - but invalid
Who the study is looking for
- aged more than 6 months.
- malignant B cell surface expression CD19 molecules.
- the KPS score over 80 points, and survival time is more than 3 months.
- greater Hgb 80 g/L.
- no contraindications to solid and cell separation
Age in the registry: 6 months to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute | Shenzhen | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.